← All indications
Neurocognitive Disorders
Diagnoses of DEMENTIA and AMNESTIC DISORDER are subsumed here. (DSM-5)
Subtype terms (6)
More specific conditions that are subtypes of Neurocognitive Disorders in the MeSH hierarchy.
- Amnesia
11 drugs (9 approved, 2 experimental)
- Cognition Disorders
336 drugs (172 approved, 164 experimental)
- Consciousness Disorders
22 drugs (17 approved, 5 experimental)
- Delirium
81 drugs (69 approved, 12 experimental)
- Dementia
252 drugs (145 approved, 107 experimental)
- Dyslexia, Acquired
Drugs by status
Phase 4 trials (6)
Phase 3 trials (1)
Phase 2 trials (13)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (19)
- Gilead Sciences
- ViiV Healthcare
- Merck
- National Institutes of Health (NIH)
- National Institute on Aging (NIA)
- McMaster University
- Monash University
- University of Toronto
- Utrecht University
- University of Bern
- Chinese University of Hong Kong
- Columbia University
- Wenzhou Medical University
- University of Basel
- City University of Hong Kong
- University of New South Wales
- University of Western Ontario
- University of Geneva
- St. Vincent's Hospital-Manhattan
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (13)
- National Institute of Mental Health (NIMH)
- Eastern Virginia Medical School
- Johns Hopkins University
- Russian Academy of Medical Sciences
- Sheppard Pratt Health System
- Old Dominion University
- BASF
- The Florey Institute of Neuroscience and Mental Health
- Lieber Institute for Brain Development (LIBD)
- NeuroActiva
- Oslo Metropolitan University
- Pre Diagnostics AS
- Ananda Hemp, Inc.
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (2)